YM BioSciences

YM BioSciences is a life sciences product development company that has identified and is developing a diverse portfolio of promising cancer-related products at various stages of development. YM BioSciences has demonstrated its expertise in regulatory and clinical trial processes, as well as its diversified business model, designed to mitigate risk while advancing clinical products toward international approval, marketing, and commercialization. YM's lead candidate drug, CYT387, is an oral, once-daily selective inhibitor of the Janus kinase (JAK) family.